explore -WSS

explore

author：explore 2025-09-05 09:18:15 - browse：9321

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Congress extends some pandemic preparedness programs

WSS

Medical device lobby: We're tired of waiting on Medicare coverage

Congress extends some pandemic preparedness programs

CDC picks Alphabet's Verily for wasterwater surveillance contract

Change Healthcare cyberattack outage could last weeks

Study points to new risk in gene therapy death of Terry Horgan

AstraZeneca loses challenge to Medicare drug price negotiation

focus

explore

entertainment

Hollywood unions extend contract negotiations for actors

CRISPR base editing slashes cholesterol levels in monkeys

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Flu, Covid vaccination rates decline, new survey data show

Alkermes shareholders re

IVG is promising — but it won’t replace IVF quite yet

In Memoriam: Notable people who died in 2023

Covid isolation guidance eased by the CDC

Virginia high school admissions case could be legal follow

6 solutions to address cancer drug shortages and others

explore

FogPharma raises $145 million in rare Series E round

With Roe v Wade overturned, abortion providers work to adapt

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

RSV vaccines may be linked to small increased risk of developing GBS

The biotech scorecard for Q4: 16 stock

FogPharma raises $145 million in rare Series E round

leisure time

focus

hotspot

explore